Annexin Pharmaceuticals

Annexin Pharmaceuticals AB is a Swedish biopharmaceutical company based in Stockholm that develops ANXV, a recombinant human Annexin A5 protein. The company’s work centers on advancing this drug candidate for vascular injury and inflammation, with additional potential applications in ophthalmology, cancer and other inflammatory diseases. It also holds patents and manufacturing know-how related to the ANXV production process.

— Annexin Pharmaceuticals
%
Lead drug candidate ANXV70% The company’s core therapeutic asset is ANXV, a recombinant Annexin A5 protein under clinical development.
Clinical development programs15% Human studies and proof-of-concept work in RVO and related indications.
Preclinical pipeline10% Earlier-stage research in cancer and other inflammatory or vascular diseases.
Intellectual property and process know-how5% Patents, licenses and manufacturing process rights supporting ANXV.

Annexin Pharmaceuticals does not sell a commercialized medicine; its direct counterparties are research sites, clinical...

  • Clinical research partnersprimary

    Trial sites, investigators and collaborators that help run ANXV proof-of-concept studies.

  • Pharmaceutical licensing partnersprimary

    Biopharma companies that may license ANXV or specific Annexin A5 rights after clinical validation.

  • Ophthalmology treatment marketsecondary

    Specialists and healthcare systems treating retinal vein occlusion and related eye disease.

  • Vascular and inflammatory disease marketsecondary

    Providers treating conditions linked to blood vessel injury and inflammation.

  • Oncology research marketemerging

    Researchers and future partners evaluating Annexin A5 applications in cancer.

Annexin Pharmaceuticals is headquartered in Stockholm, Sweden and operates as a Swedish public company...

  • •Headquartered in Stockholm, Sweden
  • •Swedish public company with local corporate base
  • •Clinical development has included studies in the United States
  • •Patent protection and manufacturing rights span multiple countries
  • •Commercial opportunity is tied to global pharma markets

The company’s strategy is to advance ANXV through proof-of-concept and Phase 2 studies in-house, then use the generated...

01
Advance ANXV clinical developmentshort-term

Clinical data is the main value driver for a development-stage biotech company.

02
Secure partnering or licensing opportunitiesmedium-term

External partners can fund later-stage development and commercialization.

03
Protect intellectual property and manufacturing capabilitylong-term

Patent coverage and process control support differentiation and deal value.

Annexin Pharmaceuticals faces the typical risks of a clinical-stage biotech company: trial failure, uncertain efficacy,...

critical

Clinical development failure

ANXV’s value depends on positive proof-of-concept and later-stage trial results.

Scope
Lead asset ANXV
Materiality
high
high

Safety or tolerability issues

Unexpected adverse events could limit dosing, enrollment or indication scope.

Scope
RVO and other clinical programs
Materiality
high
high

Intellectual property uncertainty

The business relies on patents and licensed rights around Annexin A5 and ANXV.

Scope
Patent portfolio and manufacturing process
Materiality
high
high

Funding dependence

A development-stage biotech typically consumes cash before product revenue exists.

Scope
Corporate operations and clinical programs
Materiality
high
medium

Regulatory and trial execution risk

Approvals, site execution and protocol compliance affect timing and cost of studies.

Scope
International clinical development
Materiality
medium
Intangible asset and patent impairment
A negative clinical outcome could trigger impairment charges
Share-based instruments
Fair value changes can affect equity and reported finance items
Clinical development expense timing
Quarterly comparability can be distorted by study milestones
Future licensing revenue recognition
Revenue timing will depend on contract structure and performance obligations

Annexon, Inc.

ANNX · Pharmaceutical Preparations

Anixa Biosciences Inc

ANIX · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Anebulo Pharmaceuticals, Inc.

ANEB · Pharmaceutical Preparations

ANI PHARMACEUTICALS INC

ANIP · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

: 11/08/2026